For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Five Prime Therapeutics, Inc.

USPTO Granted Patents = 71

CIPO Patents = 4

EPO Patents = 24

Trademarks = 1

Forward Citations = 400

Loading Chart...

Loading Chart...

120 inventors (with patents filed for the assignee):

Kevin Hestir (17 out of 17 patents)

Justin Wong (13 out of 13 patents)

Ernestine A Lee (13 out of 17 patents)

4. David Bellovin (12 out of 12 patents)

5. Thomas Brennan (12 out of 17 patents)

6. Lewis T Williams (11 out of 59 patents)

7. Julie Hambleton (10 out of 10 patents)

8. Emma Masteller (10 out of 11 patents)

9. Brian Wong (9 out of 27 patents)

10. Elizabeth Bosch (9 out of 9 patents)

11. Ali Sadra (9 out of 9 patents)

12. Robert Sikorski (8 out of 9 patents)

13. Andrew Rankin (7 out of 7 patents)

14. Maximiliano Vasquez (7 out of 68 patents)

15. Diane Hollenbaugh (7 out of 20 patents)

Core Competencies:

B7-H4 Antibodies

CSF1R Antibodies

Anti-FGFR2 Antibodies

CD80 Polypeptides

VISTA Binding Antibodies

Combination Cancer Therapy

Interferon-Lambda Treatment

Tissue Characterization

Gastric Cancer Treatment

Fusion Proteins

Mesothelioma Treatment

Pathological Muscle Loss

71 patents: Sort by Forward Citations

1. 12435145 - B7-H4 antibody formulations (2025-10-07),

2. 12435136 - Antibodies binding to ILT4 (2025-10-07),

3. 12365719 - CD80 extracellular domain polypeptides and their use in cancer treatment (2025-07-22),

4. 12319738 - Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer (2025-06-03),

5. 12235264 - Enhanced cytometry for tissue characterization and screening (2025-02-25),

6. 12195535 - Antibodies binding to VISTA at acidic pH (2025-01-14),

7. 12173069 - Antibodies binding to vista at acidic pH (2024-12-24),

8. 12091462 - Antibodies binding to vista at acidic pH (2024-09-17),

9. 11975046 - Medical use of interferon-lambda for the treatment of fibrosis (2024-05-07),

10. 11939383 - B7-H4 antibodies and methods and use thereof (2024-03-26),

11. 11814431 - B7-H4 antibodies and methods of use thereof (2023-11-14),

12. 11789010 - Methods of treatment with CD80 extracellular domain polypeptides (2023-10-17),

13. 11603406 - Antibodies binding to VISTA at acidic pH (2023-03-14),

14. 11566076 - Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers (2023-01-31),

15. 11559583 - Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer (2023-01-24),

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for patients with serious unmet medical needs. They have a diverse pipeline of novel antibody-based therapies targeting key pathways in oncology and immunology. Their mission is to create superior antibody medicines for the treatment of cancer and inflammatory diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

71 Patents

#18 in South San Francisco, CA

#1,178 in California

#4,950 in US

#10,081 in the World

South San Francisco, CA, United States of America

Five Prime Therapeutics, Inc.

Forward Citations = 400

120 inventors:

Kevin Hestir (17 out of 17 patents)

Justin Wong (13 out of 13 patents)

Ernestine A Lee (13 out of 17 patents)

4. David Bellovin (12 out of 12 patents)

5. Thomas Brennan (12 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…